| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$38.6M | ROE | −66.83% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $217.4M | Trading Days | 576 |
| 52W High | 9.32 |
| 52W Low | 5.04 |
| % Off High | −34.55% |
| YTD | −19.21% | 1Y | 7.53% |
| Since incept. (ann.) | 35.13% |
| Ann. Volatility (1Y) | 60.89% | Ann. Volatility (3Y) | 64.21% |
| Sharpe (1Y) | 0.42 | Sharpe (3Y) | 0.79 |
| Max Drawdown (1Y) | −35.94% | Max Drawdown (3Y) | −35.94% |
| Beta (3Y, vs SPY) | 1.13 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. | $223.0M | — |
| GALT | GALECTIN THERAPEUTICS INC | $223.3M | — |
| RNAC | Cartesian Therapeutics, Inc. | $224.8M | — |
| TTRX | Turn Therapeutics Inc. | $231.8M | — |
| NRXP | NRX Pharmaceuticals, Inc. | $232.8M | — |
| TRDA | Entrada Therapeutics, Inc. | $236.0M | — |
| NERV | Minerva Neurosciences, Inc. | $199.4M | — |
| GLSI | Greenwich LifeSciences, Inc. | $197.4M | — |
| SIGA | SIGA TECHNOLOGIES INC | $239.6M | 10.4 |
| RNA | Atrium Therapeutics, Inc. | $196.5M | — |
| INDP | Indaptus Therapeutics, Inc. |
| $195.9M |
| — |
| MGNX | MACROGENICS INC | $244.7M | — |
